## Abstract Our study aimed to determine whether riluzole, which has shown efficacy as a disease‐modifying agent in amyotrophic lateral sclerosis (ALS), is neuroprotective in a marmoset model of Parkinson's disease (PD). Reduction of energy demand by riluzole could be a rational neuroprotective str
Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease
✍ Scribed by Dr. J. Timothy Greenamyre; Robert V. Eller; Zhiming Zhang; Aliza Ovadia; Roger Kurlan; Don M. Gash
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 731 KB
- Volume
- 35
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Previous studies in the MPTP-lesioned primate model of Parkinson's disease have demonstrated that alpha(2) adrenergic receptor antagonists such as idazoxan, rauwolscine, and yohimbine can alleviate L-dopa-induced dyskinesia and, in the case of idazoxan, enhance the duration of anti-parkinsonian acti
## Abstract Glial cell line‐derived neurotrophic factor (GDNF) has been shown to possess potent neurotrophic effects on dopaminergic (DA) neurons. We attempted the transplantation of encapsulated GDNF‐producing cells to generate a stable supply of GDNF in the brain to promote neuroprotective and re
1-aminomethyl-5,6-dihydroxy-3-phenylisochroman; NMDA antagonist; CPP; 3-((6)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid